Price$0.48+0.00 (+0.00%)
2025-06-042025-08-01
News · 26 weeks70%
2025-12-072026-05-31
Mix290d
- SEC Filings1(50%)
- Other1(50%)
Latest news
25 items- SECSEC Form PRE 14C filed by Biotricity Inc.PRE 14C - BIOTRICITY INC. (0001630113) (Filer)
- SECBiotricity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - BIOTRICITY INC. (0001630113) (Filer)
- SECBiotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIOTRICITY INC. (0001630113) (Filer)
- SECSEC Form 10-Q filed by Biotricity Inc.10-Q - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDAREDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag
- PRBiotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11thCompany continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa
- SECSEC Form S-1 filed by Biotricity Inc.S-1 - BIOTRICITY INC. (0001630113) (Filer)
- SECBiotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter
- SECSEC Form 10-Q filed by Biotricity Inc.10-Q - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14thREDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors. Event: B
- PRHealth-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) UsersNew telehealth offering empowers consumers to use pre-tax healthcare funds at FSA Store® and HSA Store® to make heart health a part of everyday life with at-homemonitoring DALLAS and REDWOOD CITY, Calif., Sept. 9, 2025 /PRNewswire/ -- Health-E Commerce®, the parent brand to FSA Store® and HSA Store®, today announced a new collaboration with Biotricity® (OTCQB:BTCY), an innovative medical technology company offering clinically reliable solutions for consumers and healthcare professionals. Through this arrangement, Biotricity's continuous 24/7 wearable cardiac monitoring solution, Bioheart®, will now be available to more than 70 million consumers who are enrolled in FSAs and HSAs.
- PRBiotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring PlatformREDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and biosensing technology, are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform. The device-neutral platform, which launched in early 2025 for ambulatory cardiac monitoring, will now support ECG data from consumer wearables. This advancement enables the seamless integration and review of user data collected from smartwatches, smart rings, fitness trackers, and other mobile health products wi
- PRBiotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved MarginsREDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e
- SECSEC Form 10-Q filed by Biotricity Inc.10-Q - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14thCompany to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid
- PRBiotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within ReachFY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni
- SECSEC Form 10-K filed by Biotricity Inc.10-K - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18thCompany to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q
- SECSEC Form NT 10-K filed by Biotricity Inc.NT 10-K - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period AnalyzedREDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev
- PRBiotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease ManagementBiotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending. The expansion of the company's IP p
- SECAmendment: SEC Form 10-Q/A filed by Biotricity Inc.10-Q/A - BIOTRICITY INC. (0001630113) (Filer)
- PRBiotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn
- SECSEC Form 10-Q filed by Biotricity Inc.10-Q - BIOTRICITY INC. (0001630113) (Filer)
BTCY FAQ
6 questionsWhat does Biotricity Inc. do?
Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.Where does BTCY stock trade?
Biotricity Inc. (BTCY) is listed on NASDAQ.What sector and industry is BTCY in?
Biotricity Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about BTCY?
Biotricity Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2023-11-20. Recent price targets range from $500.00 to $600.00.What companies are similar to BTCY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BTCY side-by-side with any of them on Quantisnow.How can I track BTCY on Quantisnow?
Quantisnow aggregates Biotricity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BTCY to receive live email and push alerts on every new disclosure.